DGX stock sentiment todayQuest Diagnostics Inc
Sentiment verdict
Gossip first, financials second — NEUTRAL at 78% confidence.
Last updated · cached analysis, refreshes periodically
DGX
Quest Diagnostics IncQuest is a stable defensive play with steady dividends, but growth is capped by reimbursement pressures and high consolidation costs.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for DGX. Not financial advice.
Price · last 12 months
Gossip
The narrative centers on Quest's aggressive M&A strategy to offset the loss of COVID-19 testing revenue and a shifting landscape toward consumer-initiated testing and hospital lab outsourcing.
- ·Acquisition of LifeLabs to expand Canadian footprint
- ·PAMA (Protecting Access to Medicare Act) reimbursement rate volatility
- ·Strategic shift toward high-growth specialty testing (oncology/genomics)
Financial
Quest maintains a robust balance sheet with consistent free cash flow, though margins have faced compression post-pandemic as higher-margin COVID volumes subsided.
- ·Forward P/E: ~17.5x (Trading near 5-year historical average)
- ·Dividend Yield: ~1.8% - 2.1% (Consistent growth)
- ·Operating Margin: ~14-16% (Post-pandemic normalization)
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Strong conviction — insiders and patient capital are backing this.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Medicare reimbursement cuts under PAMA
- ·Integration risks from the $1.35B LifeLabs acquisition
- ·Labor cost inflation in phlebotomy and logistics
Peer temperature
How direct competitors stack up against DGX right now.
- HOTLHLabcorp Holdings Inc.
HOTTER — trading at a similar multiple but offers a more diversified clinical trial/drug development segment through its Fortrea spin-off synergy and faster biopharma revenue recovery.
See full analysis → - NEUTRALNEONeoGenomics, Inc.
NEUTRAL — offers higher top-line growth in specialized oncology, but lacks the profitability and defensive dividend profile of DGX.
See full analysis → - COLDOPCHOption Care Health, Inc.
COLDER — faces higher regulatory scrutiny in the infusion space and more volatile quarterly earnings compared to Quest's predictable diagnostic footprint.
See full analysis →
- DGX+0.6%
- LH+4.1%
- NEO+10.5%
- OPCH+2.2%
Analyst price target
Consensus average of 11 analysts · median 250.00
Source: StockAnalysis.com · updated 2026-09-08
AI-generated analysis for informational purposes only. Not financial advice.